Histologic predictors of survival in acquired immunodeficiency syndrome-associated Kaposi's sarcoma

George Niedt(Memorial Sloan Kettering Cancer Center), Bijan Safai(Metropolitan Hospital Center), Susan E. Krown(Memorial Sloan Kettering Cancer Center), Douglass Chapman(Memorial Sloan Kettering Cancer Center), Carlos Urmacher(Memorial Sloan Kettering Cancer Center), Patricia L. Myskowski(Memorial Sloan Kettering Cancer Center), Donna Niedzwiecki(Duke University)
Human Pathology
December 1, 1992
10.1016/0046-8177(92)90063-9
Cited by 11

Related Papers

Frequent Detection and Isolation of Cytopathic Retroviruses (HTLV-III) from Patients with AIDS and at Risk for AIDS
|Science|1984|3.6k
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With <i>KRAS</i> Wild-Type Advanced or Metastatic Colorectal Cancer
|JAMA|2017|891
Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)
|Journal of Clinical Oncology|2010|840
Kaposi sarcoma
|Nature Reviews Disease Primers|2019|707
Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee.
|Journal of Clinical Oncology|1989|483